BYSI - BeyondSpring downgraded at H.C. Wainwright despite a potential launch of Plinabulin

BeyondSpring (BYSI) is likely to receive regulatory approval for plinabulin/granulocyte colony-stimulating factor combination for the prevention of chemotherapy-induced neutropenia (“CIN”) argues H.C. Wainright analyst Joseph Pantginis.Expecting the product revenue to start from Q4 2021, Pantginis, however, downgrades the stock to neutral from buy and removes the price target, noting “a general theme of short the launch” by investors.The analyst also cites the need for a solid commercialization strategy and potential partnerships that could lift plinabulin’s commercial prospects.Despite a major catalyst in the form of Phase 3 data for Plinabulin in non-small cell lung cancer (“NSCLC”), Pantginis identifies CIN indication as the stock’s major valuation driver.BeyondSpring expects a phase 3 data readout in H1 2021 from a global clinical trial for Plinabulin as a direct anticancer agent in NSCLC.

For further details see:

BeyondSpring downgraded at H.C. Wainwright despite a potential launch of Plinabulin